17,261 trials
Congestive Heart Failure · Heart Failure, Diastolic
Primary: the Safety Profile of CAP 1002; Any Subjects Experiencing Any Safety Related Events During or Post Intracoronary Delivery and During the Follow up Period. — 0; 1…
Severe Hypertriglyceridemia
Primary: Percent Change From Baseline to Week 8 in Serum Triglyceride (TG) — -57.33; -11.85 percent change from Baseline — p=<0.001
Bladder Cancer
Primary: Change in Severity of Urinary Symptoms as Determined by the The International Prostate Symptom Score (IPSS) Questionnaire Score. — -2; -3 score on a scale
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Diabetic Nephropathies
Primary: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in 10-hour Urine After 20 Weeks of Trial Treatment — -0.069; -0.029; -0.217; 0.034…
Solid Tumors
Primary: Overall Response Rate (ORR) — 6; 1; 15; 0 Participants
Muscle Atrophy · Quality of Life
Primary: MRI Quadriceps Involved Leg — 43.87; 38.31 AU — p=.03
Prostatic Adenoma
Primary: Testosterone (T) Levels (Castrate) at Week 4 — 5; 39 Participants
Parkinson Disease
Primary: Change in Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination) Scores — -4.5714; -2.7665 units on a scale…
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Maximum-tolerated Dose (MTD) of Inotuzumab Without DLT — 4; 2; 20 Participants
Lupus Erythematosus, Systemic
Primary: Number of Participants Achieving a BILAG-2004 Index-based Combined Lupus Assessment (BICLA) Response and an OGC Dose ≤ 7.5 mg/Day and ≤ Baseline Dose of Prednisone or…
Advanced Pancreatic Cancer
Primary: Progression Free Survival (PFS) by BICR — 3.52; 1.92; 3.68; 3.22 Months
Neoplasms · Solid Tumors · Biliary Cancer
Primary: Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator — 21.0; 19.5; 25.5; 33.3 Percentage of Participants
Major Depressive Disorder
Primary: 17-Item Hamilton Depression Rating Scale Responders — 0; 0; 1; 0 Participants
Plaque Psoriasis
Primary: To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo — 19.4; 33.3; 56.4; 56.4 Percentage — p=0.0025